Press releases

22 March, 2018

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 22 March 2018, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...

20 February, 2018

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2017

Strong trend for mitochondrial disorder projects

15 February, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2 ...

15 February, 2018

Regulatory

NeuroVive decides on a Rights issue for continued drug development

Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "th ...

29 January, 2018

Regulatory

NeuroVive reports breakthrough in mitochondrial myopathy project

Lund, Sweden, 29 January 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondria ...

13 December, 2017

Regulatory

NeuroVive’s KL1333 program granted orphan drug designation by the European Commission

Lund, Sweden, 13 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the compa ...

11 December, 2017

Regulatory

NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333

Lund, Sweden, 11 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' join ...

30 November, 2017

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in ...

30 November, 2017

Regulatory

NeuroVive’s genetic mitochondrial disease program NVP015 reaches significant milestone

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demons ...

21 November, 2017

Regulatory

NeuroVive Pharmaceutical AB Interim report January – September 2017

Continued positive trend for NeuroSTAT® Business operations

8 November, 2017

Regulatory

NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation

Lund, Sweden, 8 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the Committee for Orphan Medicinal Products ...

7 November, 2017

Regulatory

NeuroVive Board Chair Resigns, New Chair Elected

Lund, Sweden, 7 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that Gregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective ...